How MES—1007 works
The MES—1007 drug-conjugate carries the drug in an inactive state until it binds to the bone. After the targeting moiety binds to bone, the drug is released where it is received by stem cells, stimulating their maturation to osteoblasts (bone-making cells).
How Safe is it?
MES—1007 avoids systemic exposure and side effects by specifically delivering drugs to the bone.
It is exceptionally well tolerated and expected to be very safe both in terms of acute and chronic toxicity and side effects. This is because the EP4a is carried in bloodstream in an inactive state until it reaches the bone. It is then released slowly and exactly where it is needed.
MES—1007 delivers an active pharmaceutical agent selectively to target tissue thereby eliminating side effects caused by systemic exposure.